公开(公告)号：US12076400B2

公开(公告)日：2024-09-03

申请号：US16887460

申请日：2020-05-29

申请人： c/o Zymeworks BC Inc.

发明人： Nina E. Weisser ,  Diana F. Hausman ,  Patrick Kaminker

IPC分类号： A61K39/395 ,  A61K31/519 ,  A61K31/7068 ,  A61K33/243 ,  A61K47/68

CPC分类号： A61K39/3955 ,  A61K31/519 ,  A61K31/7068 ,  A61K33/243 ,  A61K47/6817

摘要： Described herein is a method of treating breast cancer comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) in combination with a CDK4/6 inhibitor to a subject.

公开(公告)号：US12065489B2

公开(公告)日：2024-08-20

申请号：US17846900

申请日：2022-06-22

申请人： The Regents of the University of California

发明人： Dylan Conklin ,  Martina S. McDermott ,  Neil A. O'Brien ,  Michael J. Palazzolo ,  Dennis Slamon ,  Erika Von Euw ,  Peter Bowers

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K47/65 ,  A61K47/68 ,  A61P35/00 ,  G01N33/574

CPC分类号： C07K16/28 ,  A61K47/65 ,  A61K47/6817 ,  A61K47/6849 ,  A61P35/00 ,  G01N33/5748 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2319/00

摘要： The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

公开(公告)号：US11998613B2

公开(公告)日：2024-06-04

申请号：US17339747

申请日：2021-06-04

申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY

发明人： Shih-Hsien Chuang ,  Wei-Ting Sun ,  Ying-Shuan Lailee ,  Chun-Liang Lai ,  Wun-Huei Lin ,  Win-Yin Wei ,  Shih-Chong Tsai ,  Cheng-Chou Yu ,  Chao-Yang Huang

IPC分类号： A61K47/68 ,  A61K47/54 ,  A61P35/00

CPC分类号： A61K47/6851 ,  A61K47/545 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6889 ,  A61P35/00

摘要： The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure.

公开(公告)号：US20240156969A1

公开(公告)日：2024-05-16

申请号：US18237351

申请日：2023-08-23

申请人： Seagen Inc.

发明人： Patrick J. BURKE ,  Joel COURTER

IPC分类号： A61K47/55 ,  A61K9/00 ,  A61K9/08 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06 ,  A61K47/64 ,  A61K47/65 ,  A61K47/68 ,  A61P35/02 ,  C07K5/02

CPC分类号： A61K47/551 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06 ,  A61K47/64 ,  A61K47/65 ,  A61K47/6811 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6883 ,  A61K47/6889 ,  A61P35/02 ,  C07K5/021 ,  A61K38/00

摘要： Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

公开(公告)号：US11958908B2

公开(公告)日：2024-04-16

申请号：US17103866

申请日：2020-11-24

申请人： CRISPR THERAPEUTICS AG

发明人： Bradley R. Pearse ,  Michael Cooke ,  Anthony Boitano ,  Rahul Palchaudhuri ,  Sean McDonough ,  Rajiv Panwar ,  Jacob Glanville

IPC分类号： C07K16/28 ,  A61K35/545 ,  A61K47/68 ,  A61P35/00 ,  A61P37/06 ,  C07K7/64 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K16/2896 ,  A61K35/545 ,  A61K47/6817 ,  A61K47/6831 ,  A61K47/6849 ,  A61P35/00 ,  A61P37/06 ,  C07K7/64 ,  C07K16/2803 ,  A61K2035/124 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

公开(公告)号：US20240092894A1

公开(公告)日：2024-03-21

申请号：US18480038

申请日：2023-10-03

申请人： Dignity Health ,  Arizona Board of Regents on Behalf of Arizona State University

发明人： Rachael Sirianni ,  Rebecca Cook ,  Tsafrir Mor ,  Joseph Blattman

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K47/68 ,  A61P35/00 ,  C12N15/74 ,  C12N15/82 ,  C12N15/86

CPC分类号： C07K16/28 ,  A61K9/0019 ,  A61K47/6817 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/743 ,  C12N15/8258 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/622

摘要： Disclosed herein are compositions comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell. Also disclosed herein are methods of treating cancer in a subject, comprising: providing a composition comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell; and treating the cancer by administering a therapeutically effective dosage of the composition to the subject.

公开(公告)号：US20240033372A1

公开(公告)日：2024-02-01

申请号：US18054497

申请日：2022-11-10

申请人： Seagen Inc.

发明人： Matthew R. LEVENGOOD

IPC分类号： A61K47/68 ,  A61K47/61 ,  A61K47/60 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/496

CPC分类号： A61K47/6889 ,  A61K47/61 ,  A61K47/6883 ,  A61K47/60 ,  A61K47/6803 ,  A61K31/496 ,  A61K47/6809 ,  A61K47/6849 ,  A61K31/4745 ,  A61K31/704 ,  A61K47/6817

摘要： The present disclosure provides, inter alia, multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units that are constructed in a site-specific matter via “orthogonal” deprotection and drug loading. Also provided are, Protected Linking Assembly Units, which allow for ‘orthogonal’ deprotection and construction of MD-ADCs and LA Units of the present disclosure.

公开(公告)号：US20240016960A1

公开(公告)日：2024-01-18

申请号：US18351291

申请日：2023-07-12

申请人： DEFENCE THERAPEUTICS INC.

发明人： Simon BEAUDOIN

IPC分类号： A61K51/10 ,  A61K47/54 ,  A61K47/64 ,  A61K47/68 ,  A61K45/00

CPC分类号： A61K51/1045 ,  A61K47/554 ,  A61K47/645 ,  A61K47/6817 ,  A61K47/6851 ,  A61K45/00

摘要： The present description relates to a conjugated compound an antibody covalently linked to enhancer moiety composed by a nuclear localization sequence (NLS), covalently linked to a sterol variant, such as cholic acid (ChAc) or a variant thereof. The enhancer moiety as encompassed herein is able to induce endosome escape of the compound-conjugates by direct membrane destabilization or indirectly by ROS and ceramide production which destabilize endosome-lysosome membrane. The conjugated compound can further comprise payload.

公开(公告)号：US20230391852A1

公开(公告)日：2023-12-07

申请号：US18033656

申请日：2021-10-26

申请人： The U.S.A., as Represented by the Secretary, Department of Health and Human Services

发明人： Mitchell Ho ,  Jessica Diana Hong

IPC分类号： C07K16/10 ,  A61K47/68 ,  G01N33/569

CPC分类号： C07K16/1003 ,  A61K47/6841 ,  A61K47/6817 ,  G01N33/56983 ,  C07K2317/569 ,  C07K2319/30 ,  C07K2317/31 ,  C07K2317/92 ,  C07K2317/22 ,  C07K2317/76 ,  G01N2469/10 ,  G01N2333/165

摘要： Polypeptides that specifically bind the spike (S) protein of human coronavirus, selected from six camel VHH single domain antibody phage display libraries, are described. The S protein-specific polypeptides disrupt binding of the SARS-CoV-2 and/or SARS-CoV S protein to the cellular receptor ACE2, which is important for neutralization of the virus. Use of the S protein-specific polypeptides for the diagnosis and treatment of SARS-CoV-2 and/or SARS-CoV is described.

公开(公告)号：US20230390413A1

公开(公告)日：2023-12-07

申请号：US18318062

申请日：2023-05-16

申请人： THE TEXAS A&M UNIVERSITY SYSTEM ,  Board of Regents of the University of Texas System

发明人： Elizabeth Sally WARD OBER ,  Raimund Johannes OBER ,  Jeffrey Che-Wei KANG ,  Wei SUN ,  Ran LI

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/32

CPC分类号： A61K47/6855 ,  A61K47/6817 ,  A61P35/00 ,  C07K16/32 ,  A61K38/00

摘要： Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.